Corporate Presentation
About ZP
We strive to be the world's best peptide drug
discovery and development company
Dasiglucagon²
•
.
Stabilized
Prevention of
aggregation
Lixisenatide¹
•
First SIP-tail
modified GLP-1
analog
Glepaglutide
GLP-2 analog
•
Stabilized
Long-acting
Survodutide³
GCGR/GLP1R
• Acylation for
long half-life
Optimized
formulation space
Dapiglutide
GLP1/GLP2
• Acylation for
long half-life
Petrelintide
Amylin analog
• Acylation for
long half-life
Co-formulation
potential
ZP6590
GIP analog
Enhanced
drug properties
Engineered
dual pharmacology
• Acylation for
long half-life
• Co-formulation
potential
ZEAL&
ZEALAND PHARMA
Designed
novel peptide modalities
ZP10000
a4ẞ7 inhibitor
Cyclic peptide
• Oral
bioavailability
ZP10068
Complement C3
inhibitor4
Sweet spot for
peptide
therapeutics
ZP9830
Kv1.3 blocker
Engineered
from biological
toxin
marketed
1 Marketed globally by Sanofi.
clinical development
preclinical development / discovery research
2 Zegalogue® (dasiglucagon) for injection licensed to Novo Nordisk: DKK 242.5 million outstanding potential development, regulatory manufacturing and sales milestones + high single to low double digit % royalties on global sales;
Zealand is responsible for certain activities to support approval outside the U.S., reimbursed by Novo Nordisk; Zealand retains all non-licensed intellectual property rights to the company's other dasiglucagon development programs
3 Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally (subject to Zealand's co-promotion rights in the Nordic countries): EUR 315
million outstanding potential development, regulatory and commercial milestones + high single to low double digit % royalties on global sales
4 Lead candidate under an exclusive agreement between Zealand and Alexion: USD $610 million in potential development, regulatory and commercial milestones + high single to low double digits % royalties on net sales
5
слView entire presentation